Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment

Emergent BioSolutions Inc EBS has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) plasma-derived therapy.
Related: Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study.
The trial will assess the therapy as a potential outpatient treatment for patients at high risk of progression to severe disease, including adults 55 and older and those who are immunocompromised.
The NIAID-sponsored INSIGHT-012 study will evaluate the safety and efficacy of hyperimmune globulin products derived from plasma of individuals who have recovered from COVID-19 and have developed neutralizing antibodies.
The randomized controlled clinical trial assigns participants to receive infusions of either a placebo or one of two hyperimmune globulin products, including Emergent's COVID-HIG, in addition to standard of care in all groups.
The trial plans to enroll approximately 800 patients.
Price Action: EBS shares closed 1.43% lower at $62.76 on Tuesday.

Momentum64.28

Growth9.24

Quality-

Value33.85

Short

Medium

Long